Refractory fibromyalgia.
Consensus definition
Musculoskeletal pain
Refractory fibromyalgia
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
23
04
2021
accepted:
12
06
2021
revised:
09
06
2021
pubmed:
26
6
2021
medline:
14
8
2021
entrez:
25
6
2021
Statut:
ppublish
Résumé
In the medical literature, there are only a few references on refractory fibromyalgia and there is no consensus definition available on this concept. Some definitions of refractory fibromyalgia have been proposed based on the lack of response to a number of medications, and perhaps the most appropriate term is treatment-refractory fibromyalgia. To achieve the definition of treatment-refractory fibromyalgia, it is necessary to consider several previous steps, such as making sure the diagnosis has been made properly and a differential diagnosis with entities that can mimic fibromyalgia symptoms (including complete physical examination and laboratory test) has been made. The possibility that another factor that alters the response to treatment should be investigated, and in particular review all prescribed medication and search for some non-medical reasons that could mask the response to treatment (e.g., legal compensation). The definition of refractory fibromyalgia is complex and probably should include a lack of response to a specified number of drugs or to combination therapy with at least two non-pharmacological measures. In this article, it is not our purpose to present a formal definition, but to raise the possible bases for this purpose. We believe that it is a subject that must be discussed extensively before reaching a consensus definition. Key Points • There is no appropriate definition to classify fibromyalgia patients who do not respond to the usual pharmacological and non-pharmacological measures according to the national or international guidelines. • A consensus definition is required to classify these patients, which could help standardize future management strategies. In this article, we propose the bases on which refractory fibromyalgia could be defined.
Identifiants
pubmed: 34169373
doi: 10.1007/s10067-021-05818-0
pii: 10.1007/s10067-021-05818-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3853-3858Informations de copyright
© 2021. International League of Associations for Rheumatology (ILAR).
Références
Häuser W, Fitzcharles MA (2018) Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci 20(1):53
doi: 10.31887/DCNS.2018.20.1/whauser
Arnold LM, Gebke KB, Choy EHS (2016) Fibromyalgia: management strategies for primary care providers. Int J Clin Pract 70(2):99–112
doi: 10.1111/ijcp.12757
Heymann RE, Paiva ES, Martinez JE et al (2017) New guidelines for the diagnosis of fibromyalgia. Rev Bras Reumatol 57:s467-476
doi: 10.1016/j.rbr.2017.05.006
Ablin JN, Buskila D (2015) Update on the genetics of the fibromyalgia syndrome. Best Pract Res Clin Rheumatol 29(1):20–28
doi: 10.1016/j.berh.2015.04.018
Bennett R (2016) Shining a light on fibromyalgia treatment. Nat Rev Rheumatol 12(10):568–569
doi: 10.1038/nrrheum.2016.149
Copay AG, Subach R, Glassman SD et al (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7(5):541–546
doi: 10.1016/j.spinee.2007.01.008
Choy EH, Arnold LM, Clauw DJ et al (2009) Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 36:2330–2334
doi: 10.3899/jrheum.090368
Revicki D, Hays RD, Cella D et al (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102–109
doi: 10.1016/j.jclinepi.2007.03.012
Bennet RM, Bushmakin AG, Cappelleri JC et al (2009) Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 36:1304–1311
doi: 10.3899/jrheum.081090
Geisser ME, Clauw DJ, Strand V et al (2010) Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 149:373–378
doi: 10.1016/j.pain.2010.02.043
Arnold LM, Zlateva G, Sadosky A et al (2011) Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med 12:260–267
doi: 10.1111/j.1526-4637.2010.01047.x
Hudson JI, Arnold LM, Bradley LA et al (2009) What makes fibromyalgia patients feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of four, randomized, placebo-controlled trials of duloxetine. J Rheumatol 36:2517–2522
doi: 10.3899/jrheum.090139
Arnold LM, Williams DA, Hudson JI et al (2012) Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum 64(3):885–894
doi: 10.1002/art.33360
Nuesch E, Häuser W, Bernardy K et al (2013) Comparative efficacy of pharmacological and nonpharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 72:955–962
doi: 10.1136/annrheumdis-2011-201249
Holman A (1998) Effect of lorazepam on pain score for refractory fibromyalgia. Arthritis Rheum 41(9)
Dworkin R, Sharma U, Stacey B et al (2005) Long-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patients. J Pain 6(3):S30
doi: 10.1016/j.jpain.2005.01.116
Stacey BR, Emir B, Petersel D et al (2010) Pregabalin in treatment-refractory fibromyalgia. Open Rheumatol J 4:35
doi: 10.2174/1874312901004010035
Fitzcharles MA, Ste-Marie PA, Goldenberg DL et al (2013) Canadian guidelines for the diagnosis and management of Fibromyalgia syndrome: executive summary. Pain Res Manag 18(3):119–126
doi: 10.1155/2013/918216
Fitzcharles MA, Shir Y, Ablin JN el at (2013) Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. Evid Based Complement Alternat Med 2013:485272
Salaffi F, Gerardi MC, Atzeni F et al (2017) The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. Rheumatol Int 37(12):2035–2042
doi: 10.1007/s00296-017-3792-4
Fitzcharles MA, Perrot S, Häuser W (2018) Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain 22(9):1565–1576
doi: 10.1002/ejp.1252
Häuser W, Perrot S, Sommer C et al (2017) Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep 2(3)
López-Medina C, Moltó A (2020) Comorbid pain in axial spondyloarthritis, including fibromyalgia. Ther Adv Musculoskelet Dis 12:1759720X20966123
doi: 10.1177/1759720X20966123
Arendt-Nielsen L, Nie H, Laursen MB et al (2010) Sensitization in patients with painful knee osteoarthritis. Pain 149(3):573–581
doi: 10.1016/j.pain.2010.04.003
Fingleton C, Smart K, Moloney N et al (2015) Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartil 23:1043–1056
doi: 10.1016/j.joca.2015.02.163
Bazzichi L, Rossi A, Giuliano T et al (2007) Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 26(12):2115–2120
doi: 10.1007/s10067-007-0636-8
Haliloglu S, Ekinci B, Uzkeser H et al (2017) Fibromyalgia in patients with thyroid autoimmunity: prevalence and relationship with disease activity. Clin Rheumatol 36(7):1617–1621
doi: 10.1007/s10067-017-3556-2
Tagoe CE, Sheth T, Golub E et al (2019) Rheumatic associations of autoimmune thyroid disease: a systematic review. Clin Rheumatol 38(7):1801–1809
doi: 10.1007/s10067-019-04498-1
Vidal M, Lane NE (2020) The importance of vitamin D. Rheumatol Orthop Med 5. https://doi.org/10.15761/ROM.1000171
Vidal LF, Morales R, Cueva C et al (2019) Serum levels of vitamin D in women treated at rheumatology services in Lima. Int J Clin Rheumatol 14(3):105–112
Häuser W, Perrot S, Clauw DJ et al (2018) Unravelling fibromyalgia—steps toward individualized management. J Pain 19(2):125–134
doi: 10.1016/j.jpain.2017.08.009
Affaitati G, Costantini R, Fabrizio A et al (2011) Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain 15(1):61–69
doi: 10.1016/j.ejpain.2010.09.002
Häuser W, Ablin J, Perrot S et al (2017) Management of fibromyalgia: practical guides from recent evidence-based guidelines. Pol Arch Intern Med 127(1):47–56
doi: 10.20452/pamw.3877
Smith JD, Terpening CM, Schmidt SO et al (2001) Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 35(6):702–706
doi: 10.1345/aph.10254
Dodd S, Horgan D, Malhi GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89(1–3):1–11
doi: 10.1016/j.jad.2005.08.012
Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53(8):649–659
doi: 10.1016/S0006-3223(03)00231-2
Souery D, Papakostas GI, Trivedi MH (2006) Treatment-resistant depression. J Clin Psychiatry 67(16)